Loading…
We use essential cookies (authentication, your saved goals/stack) by default. With your permission we’ll also enable privacy-respecting analytics (Vercel Web Analytics, anonymous load-time metrics) and error-replay diagnostics (Sentry — DOM snapshots only when an error fires) so we can fix bugs faster. Learn more about cookies
Head-to-head evidence comparison — which supplement is right for you?
Dapagliflozin vs Inclisiran (Leqvio): Dapagliflozin has the stronger overall evidence (4.4 vs 4.1/10); they're alternatives for support heart health — the best pick depends on your goals. Take the 60-second quiz for a pick tailored to your goals.
Dapagliflozin wins 2 of 3 categories. Both are solid choices — the best pick depends on your specific goals.
Verdict
Too few graded studies
Top outcomes
Verdict
Too few graded studies
Top outcomes
Shared outcomes (1)
Outcomes where both Dapagliflozin and Inclisiran (Leqvio) have evidence — compare verdict strength side-by-side.
Off-label use mirrors approved dosing (10 mg once daily) under a clinician. A prescription drug; not an approved longevity regimen.
Morning
Oral tablet (dapagliflozin)
284 mg (300 mg inclisiran sodium) by subcutaneous injection administered by a healthcare professional on day 1, again at day 90 (month 3), then every 6 months thereafter. A prescription drug; this is the approved regimen, not a self-directed supplement protocol.
Any time of day
Prefilled subcutaneous injection (inclisiran 284 mg)
Weeks
Months to years
Months to years
Weeks to months
Weeks to months; sustained
Ongoing
Outcomes trials ongoing
Around each injection
Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction.
The New England journal of medicine (2019) · Rct · n=4744
DAPA-HF randomized trial in heart failure with reduced ejection fraction
Dapagliflozin in Patients with Chronic Kidney Disease.
The New England journal of medicine (2020) · Rct · n=4304
DAPA-CKD randomized trial in a broad, largely non-diabetic chronic-kidney-disease population
Dapagliflozin in Heart Failure with Mildly Reduced or Preserved Ejection Fraction.
The New England journal of medicine (2022) · Rct · n=6263
DELIVER randomized trial extending dapagliflozin to mildly reduced and preserved ejection fraction
Two Phase 3 Trials of Inclisiran in Patients with Elevated LDL Cholesterol.
The New England journal of medicine (2020) · Rct · n=3178
ORION-10 and ORION-11 randomized, placebo-controlled phase 3 trials in atherosclerotic cardiovascular disease / high risk
Inclisiran for the Treatment of Heterozygous Familial Hypercholesterolemia.
The New England journal of medicine (2020) · Rct · n=482
ORION-9 randomized, placebo-controlled phase 3 trial in heterozygous familial hypercholesterolemia
Inclisiran in Patients at High Cardiovascular Risk with Elevated LDL Cholesterol.
The New England journal of medicine (2017) · Rct · n=501
ORION-1 phase 2, double-blind, placebo-controlled, multiple-ascending-dose trial
Dapagliflozin has a higher evidence score (4.4/10 vs 4.1/10) and wins in 2 of 3 categories.
For support heart health, Dapagliflozin has a higher relevance score (72 vs 70).
No documented interaction was found in the data searched. This does not establish that this exact combination is safe.
The right pick depends on your goals. Answer a few quick questions for a personalised recommendation — or dig into the full evidence on each.